In one of the biggest advances against leukemia and other blood cancers in many years, doctors are reporting unprecedented success by using gene therapy to transform patients’ blood cells into soldiers that seek and destroy cancer.
A few patients with one type of leukemia were given this one-time, experimental therapy several years ago and some remain cancer-free today. Now, at least six research groups have treated more than 120 patients with many types of blood and bone marrow cancers, with stunning results.
“It’s really exciting,” said Janis Abkowitz, blood diseases chief at the University of Washington in Seattle and president of the American Society of Hematology. “You can take a cell that belongs to a patient and engineer it to be an attack cell.”
In one study, all five adults and 19 of 22 children with acute lymphocytic leukemia (ALL), had a complete remission, meaning no cancer could be found after treatment, although a few have relapsed since then.
These were gravely ill patients out of options. Some had tried multiple bone marrow transplants and up to 10 types of chemotherapy or other treatments.
Cancer was so advanced in eight-year-old Emily Whitehead of Philipsburg, Pennsylvania, that doctors said her major organs would fail within days. She was the first child given the gene therapy and shows no sign of cancer today, nearly two years later.
Results on other patients with myeloma, lymphoma and chronic lymphocytic leukemia (CLL), will be reported at the hematology group’s conference that started on Saturday in New Orleans.
Doctors say this has the potential to become the first gene therapy approved in the US and the first for cancer worldwide. Only one gene therapy is approved in Europe, for a rare metabolic disease.
The treatment involves filtering patients’ blood to remove millions of white blood cells called T-cells, altering them in the lab to contain a gene that targets cancer, and returning them to the patient in infusions over three days.
“What we are giving essentially is a living drug” — permanently altered cells that multiply in the body into an army to fight the cancer, said David Porter, a University of Pennsylvania scientist who led one study.
Several drug and biotech companies are developing these therapies. Penn has patented its method and licensed it to Switzerland-based Novartis AG. The company is building a research center on the Penn campus in Philadelphia and plans a clinical trial next year that could lead to federal approval of the treatment as soon as 2016.
Nearly 49,000 new cases of leukemia, 70,000 cases of non-Hodgkin lymphoma and 22,000 cases of myeloma are expected to be diagnosed in the US this year.
Many patients are successfully treated with chemotherapy or bone marrow or stem cell transplants, but transplants are risky and donors cannot always be found. So far, gene therapy has been tried on people who were in danger of dying because other treatments had failed.
The gene therapy must be made individually for each patient, and lab costs now are about US$25,000, without a profit margin. That is still less than many drugs to treat these diseases and far less than a transplant.
The treatment can cause severe flu-like symptoms and other side effects, but these have been reversible and temporary, doctors say.
Penn doctors have treated the most cases so far — 59. Of the first 14 patients with CLL, four had complete remissions, four had partial ones and the rest did not respond. However, some partial responders continue to see their cancer shrink a year after treatment.
“That’s very unique to this kind of therapy” and gives hope the treatment may still purge the cancer, Porter said.
Another 18 CLL patients were treated and half have responded so far.
Penn doctors also treated 27 ALL patients. All five adults and 19 of the 22 children had complete remissions, an “extraordinarily high” success rate, said Stephan Grupp at the Children’s Hospital of Philadelphia.
Six have since relapsed, though, and doctors are pondering a second gene therapy attempt.
At the National Cancer Institute, James Kochenderfer and others have treated 11 patients with lymphoma and four with CLL, starting roughly two years ago. Six had complete remissions, six had partial ones, one has stable disease and it is too soon to tell for the rest.
Ten other patients were given gene therapy to try to kill leukemia or lymphoma remaining after bone marrow transplants. These patients got infusions of gene-treated blood cells from their transplant donors instead of using their own blood cells. One had a complete remission and three others had significant reduction of their disease.
Republican US lawmakers on Friday criticized US President Joe Biden’s administration after sanctioned Chinese telecoms equipment giant Huawei unveiled a laptop this week powered by an Intel artificial intelligence (AI) chip. The US placed Huawei on a trade restriction list in 2019 for contravening Iran sanctions, part of a broader effort to hobble Beijing’s technological advances. Placement on the list means the company’s suppliers have to seek a special, difficult-to-obtain license before shipping to it. One such license, issued by then-US president Donald Trump’s administration, has allowed Intel to ship central processors to Huawei for use in laptops since 2020. China hardliners
Conjoined twins Lori and George Schappell, who pursued separate careers, interests and relationships during lives that defied medical expectations, died this month in Pennsylvania, funeral home officials said. They were 62. The twins, listed by Guinness World Records as the oldest living conjoined twins, died on April 7 at the Hospital of the University of Pennsylvania, obituaries posted by Leibensperger Funeral Homes of Hamburg said. The cause of death was not detailed. “When we were born, the doctors didn’t think we’d make 30, but we proved them wrong,” Lori said in an interview when they turned 50, the Philadelphia Inquirer reported. The
RAMPAGE: A Palestinian man was left dead after dozens of Israeli settlers searching for a missing 14-year-old boy stormed a village in the Israeli-occupied West Bank US President Joe Biden on Friday said he expected Iran to attack Israel “sooner, rather than later” and warned Tehran not to proceed. Asked by reporters about his message to Iran, Biden simply said: “Don’t,” underscoring Washington’s commitment to defend Israel. “We are devoted to the defense of Israel. We will support Israel. We will help defend Israel and Iran will not succeed,” he said. Biden said he would not divulge secure information, but said his expectation was that an attack could come “sooner, rather than later.” Israel braced on Friday for an attack by Iran or its proxies as warnings grew of
A prominent Christian leader has allegedly been stabbed at the altar during a Mass yesterday in southwest Sydney. Bishop Mar Mari Emmanuel was saying Mass at Christ The Good Shepherd Church in Wakeley just after 7pm when a man approached him at the altar and allegedly stabbed toward his head multiple times. A live stream of the Mass shows the congregation swarm forward toward Emmanuel before it was cut off. The church leader gained prominence during the COVID-19 pandemic, amassing a large online following, Officers attached to Fairfield City police area command attended a location on Welcome Street, Wakeley following reports a number